AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02953015 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Transcutaneous Electrical Nerve Stimulation (TENS) of the upper trapezius muscle will be applied by a portable machine Master 932 (Elettronica Pagani SRL, Milan, Italy) that generates symmetric, bi-phasic rectangular pulses with 140μ sec duration. The current frequency will be set at 150 Hz and intensity will be increased up to patient's perception of paresthesia. The negative electrode will be placed on the active TrPs of the upper trapezius muscle and the positive one was on acromial tendon insertional site. The total duration of each application will be 20 minutes. Treatment frequency and duration will be the same of the EG treatment (1 session/week for 4 weeks). Each session will consist of 20 min of TENS and 10 min of resting in sitting position with the head lean on a pillow.
Study NCT02953015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (Prophylaxis therapy)
Description: Prophylaxis therapy with OnabotulinumtoxinA according to the PREEMPT protocol (155U every three months into 31 injection site).
Study NCT02953015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA (Prophylaxis therapy)
Description: Prophylaxis therapy with OnabotulinumtoxinA according to the PREEMPT protocol (155U every three months into 31 injection site).
Study NCT03726073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical acupoint stimulation(TEAS) and auricular acupressure
Description: Bilaterally Hegu (LI4), Neiguan (PC6) and Zusanli (ST36) will be used as the TEAS acupoints. Six acupoints (Shenmen, Point Zero, subcortex, heart, liver, and endocrine) located on ears will be used as the auricular acupressure points.
Study NCT03726073 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual care
Description: Patients in this group only receive usual care developed by the study hospital
Study NCT03227393 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga training
Description: Subjects will complete in class yoga training weekly for 8 weeks with additional practice at home
Study NCT04301726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine Oral Tablet [Austedo]
Description: The participants randomized to this group will receive oral deutetrabenazine for 8 weeks. Week 1: 6 mg tab once daily; Week 2: 6 mg tab (BID); Week 3: 9 mg tab (BID); Week 4: 12 mg tab (BID); Week 5: 15 mg (6 mg tab + 9 mg tab BID); Week 6: 18 mg (9 mg tab + 9 mg tab BID); Week 7: 21 mg (9 mg tab + 12 mg tab BID); Week 8: 24 mg (12 mg tab BID).
Study NCT04301726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: The participants randomized to this group will receive oral placebo for 8 weeks. Week 1: 6 mg tab once daily; Week 2: 6 mg tab (BID); Week 3: 9 mg tab (BID); Week 4: 12 mg tab (BID); Week 5: 15 mg (6 mg tab + 9 mg tab BID); Week 6: 18 mg (9 mg tab + 9 mg tab BID); Week 7: 21 mg (9 mg tab + 12 mg tab BID); Week 8: 24 mg (12 mg tab BID).
Study NCT03074604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aortic no-touch OPCABG
Description: (Study arm 1) In this intervention only the internal mammary artery grafts will be used (i.e. left internal mammary artery graft, right internal mammary artery graft, or a Y-graft that uses right internal mammary artery graft anastomosed onto left internal mammary artery graft to allow for a wide territory of myocardial revascularization). However, in the rare event that the aforementioned approach is insufficient to reach all target vessels, a reversed (great) saphenous vein graft may be used to extend the left internal mammary artery graft or the right internal mammary artery graft.
Study NCT03074604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OPCABG with partial clamp applying carbon dioxide
Description: (Study arm 2) In this intervention chest cavity will be insufflated with carbon dioxide at a flow above 5 l/min during the entire surgical procedure.
Study NCT03074604 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OPCABG with partial clamp
Description: (Study arm 3) This is the control arm undergoing traditional OPCABG with partial clamp.
Study NCT03012841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arctic Front Advance Cardiac CryoAblation Catheter
Description: Cryoablation
Study NCT02404402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LED
Description: Low Level Light Therapy
Study NCT02404402 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham LED
Description: Inactive (sham) LED treatment
Study NCT02665819 — intervention group
Intervention type: OTHER
Intervention: Pediatric cancer women survivors
Description: Women will incur a blood taking to obtain fertility indication.
Study NCT03102957 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: functional MRI
Study NCT03102957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional MRI
Study NCT04646018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar Spine Manipulation
Description: Lumbar non-thrust manipulation is a passive movement that is performed with a rhythm and a grade in a manner in which the patient is able to prevent the technique from being performed.
Study NCT04646018 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Manipulation
Description: Lumbar non-thrust manipulation without force applied
Study NCT04655781 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: idiopathic macular hole (MH) surgery
Description: Idiopathic Macular Hole Surgery with Different Internal Limiting Membrane Peeling Patterns
Study NCT06101186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NPECP based on NSM
Description: A comprehensive training booklet which integrated NPECP and NSM principles was sent to five experts for their evaluation and feedback. Among these experts, one was a physician who specialized in obstetrics and gynecology while the remaining individuals were nurses. Group training sessions were conducted online, with each group comprising 4-6 participants. These sessions spanned four weeks, with each session being held weekly and lasting for approximately 60-90 minutes. The training covered various topics - including pregnancy, pregnancy-related changes, pregnancy danger signs, premature birth, stress, stress symptoms, stress coping strategies, childbirth, the postpartum period and the challenges of parenting (particularly when dealing with a pre-term baby)
Study NCT01695005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3039478
Description: Administered orally
Study NCT01695005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered orally
Study NCT03783117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic field treatment
Description: The MBPL device for clinical trials is made with modification of an electromagnet: A bore of 10cm diameter was made to go through the frame and poles. The device can produce a magnetic field close to 1.0 T inside the bore, which is along the axis direction. The trial for each subject takes about 20-30 minutes. To start with, the subject's blood pressure is measured first as the baseline. Afterwards, the subject places his/her right arm into the bore of the electromagnet for treatment while the blood pressure is monitored with the left arm. The magnetic treatment lasts about 15 minutes and will lower the subject's blood pressure. In order to see how long the effect lasts, the subject needs to return and measure the blood pressure again 24 hours after the treatment. The clinical trials are non-invasive. There is no medicine or surgery involved.
Study NCT00052078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline (SRT)
Description: Participants were treated with sertraline.
Study NCT03466047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CHO stomach
Description: encapsulated CHO stomach
Study NCT03466047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CHO distal small intestine
Description: encapsulated CHO distal small intestine
Study NCT03466047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fat stomach
Description: encapsulated Fat stomach
Study NCT03466047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fat distal small intestine
Description: encapsulated Fat distal small intestine
Study NCT04151589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ANGEL Intervention Package and Toolbox
Description: The interventional measures include emergency work flow management app on smartphone, specialized training, assessment of quality improvement outcomes and feedback on a regular basis, patient-centred management frame based lean six-sigma, and other specialised approach.
Study NCT06530004 — intervention group
Intervention type: DRUG
Intervention: Rituximab
Description: B lymphocyte reconstitution was performed regularly after the administration of rituximab, and 1-4 doses of rituximab were given according to the exhaustion of B cells in children.
Study NCT02930395 — intervention group
Intervention type: PROCEDURE
Intervention: serum S100B assay
Study NCT00317018 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Evidence-Based Quality Improvement
Description: The implementation intervention is known as Evidence-Based Quality Improvement (EBQI). EBQI is an adaptation of the Plan-Do-Study-Act cycles of Continuous Quality Improvement that emphasizes empirical evidence and the involvement of clinical and implementation experts (i.e., researchers). In the EBQI implementation intervention, both researchers (clinical and implementation experts) and local staff participate fully in the quality improvement process, with the researchers facilitating rather than dictating implementation efforts. Using EBQI methods, researchers and local staff adapt evidence-based practices for local resources, needs and preferences while maintaining fidelity to the evidence-base. PDSA cycles are used to continuously revise the adapted evidence-based practice based on feedback during pilot tests.
Study NCT02775370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib Mesylate will be administered orally at 500 mg once daily for 5 consecutive days, and this was followed by a 2-day rest every week; each cycle consisted of 28 days
Study NCT03405090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: 100 mcg fentanyl citrate will be inhaled via nebulizer
Study NCT03405090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combivent
Description: 0.5 mg ipratropium bromide + 2.5 mg salbutamol will be inhaled via nebulizer
Study NCT03176264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: 400 mg every 4 weeks
Study NCT03176264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 5 mg/kg every 2 weeks
Study NCT03176264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Combination of chemotherapy administered every 2 weeks: oxaliplatin (85mg/m2), 5-Fluorouracil (2400mg/m2) and folinic acid (=leucovorin, 400mg/m2)
Study NCT00230750 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/H5N1 Vaccine
Description: Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 90-mcg/mL. Dosages: 45 mcg or 90 mcg administered intramuscularly.
Study NCT00230750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo.
Study NCT02679326 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Therapeutic ultrasound
Study NCT02679326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound
Study NCT03156881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Osteopathic Treatment
Description: The study objectives is to observe a difference and improvement of liver function based on liver enzyme count from blood work after osteopathic treatments. Also to observe an improvement in the patients quality of life after receiving treatment and in their readiness to change.~Osteopathy is a type of manual therapy that uses gentle manipulations taking into consideration of the whole person when treating. For example if the liver is being treated, osteopaths look for mobility, to carry out its proper function. However one will also assess its interrelationships that can influence the liver such as its neighbours, articulating structures, example the diaphragm as well as its neurological input from T5-T9 for instance.
Study NCT01644864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.375% ROPIVACAINE
Study NCT01644864 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03112109 — intervention group
Intervention type: OTHER
Intervention: 'New care'
Description: Frail elderly receiving care within new organisational models delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform) as provided by pilot sites individually.
Study NCT01955187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACROLIMUS
Description: Initial dose: 0.05 mg/Kg/day, adjusted to achieve blood trough levels of 5-7 ng/ml) for six months. Starting at the end of month 6, tacrolimus dosage will be reduced by 25% per month, resulting in a complete withdrawal at the end of month 9.
Study NCT01955187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RITUXIMAB
Description: A dose 1 g IV will be given during month 6 (at day 180), before the onset of tacrolimus dose reduction
Study NCT01955187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: METHYLPREDNISOLONE
Description: Month 1: 1g IV methylprednisolone daily for three doses (days 1, 2, and 3), Oral methylprednisolone (0.5mg/kg/day) for 27 days (days 4 to 30). Months 3, and 5: Repeat Month 1.
Study NCT01955187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CYCLOPHOSPHAMIDE
Description: Month 2: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days. Months 4, and 6: Repeat month 2.
Study NCT03251729 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical cerclage
Description: Transvaginal cervical cerclage placed between 18 0/7 - 23 6/7 weeks
Study NCT03251729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Description: Vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks
Study NCT03251729 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vaginal progesterone
Description: Vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks
Study NCT02963090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan at 1.25mg/m2 on days 1 to 5 every 21-days until progression of disease or unacceptable toxicities.~Patients with progression of disease by RECIST 1.1 will be allowed cross over to receive pembrolizumab 200 mg IV every 21-days for up to 1 year until progression of disease or unacceptable toxicities.
Study NCT02963090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV every 21-days until progression of disease or unacceptable toxicities.
Study NCT02963090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 200 mg IV every 21-days until progression of disease or unacceptable toxicities.
Study NCT01863147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin and acarbose
Description: Sitagliptin group: The intervention drug is sitagliptin. Acarbose group: The intervention drug is acarbose.
Study NCT01863147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin and acarbose
Description: Sitagliptin group: The intervention drug is sitagliptin. Acarbose group: The intervention drug is acarbose.
Study NCT04038918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive muscle relaxation exercise
Description: In addition to standard postoperative rehabilitation, intervention group will receive PMR exercises focusing on reduce overall body tension, anxiety. The intervention group will perform the PMR exercise in accompanying with a qualified physiotherapist for postoperative 3 days (2 times/day; along 30 minutes for one session).
Study NCT04038918 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard postoperative physiotherapy program
Description: After surgery, patients will receive standard postoperative rehabilitation program including active-assistive and active range of motion exercises, isometric and isotonic strengthening exercises, gait training and transfer training.
Study NCT04038918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard postoperative physiotherapy program
Description: After surgery, patients will receive standard postoperative rehabilitation program including active-assistive and active range of motion exercises, isometric and isotonic strengthening exercises, gait training and transfer training.
Study NCT04340661 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BIOintestil
Description: Ginger ryzoma powder and Palmrose essential oil (Cymbopogon Martinii)
Study NCT04340661 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Cornstarch
Study NCT00767390 — intervention group
Intervention type: DEVICE
Intervention: ACL Patch
Description: Observe and characterize the changes in relative conductivity between the six ACL patches over period of six hours. Investigation only involves passive data collection on pressure impact and adhesiveness properties of ACL patches.
Study NCT03025750 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV-Al SSI
Description: Total of three primary injections of IPV-Al SSI, one at 2, 4 and 6 months of age
Study NCT03025750 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV SSI
Description: Total of three primary injections of IPV SSI, one at 2, 4 and 6 months of age
Study NCT00429780 — intervention group
Intervention type: BIOLOGICAL
Group type: NO_INTERVENTION
Intervention: Alum-ALM + BCG
Description: Alum-ALM + BCG 200 ug per injection
Study NCT02845232 — intervention group
Intervention type: OTHER
Intervention: Transfusion
Description: The number and type of blood products administered were registered from the time of diagnosis to the time of death corresponding for all patients to the time of last follow-up. Transfusion of a single unit of packed red blood cell (PRBC) or one whole blood-derived platelet concentrate (PC) or fresh frozen plasma (FFP) was considered a transfusion event and considered for statistical analysis.
Study NCT02617953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS(A)
Description: repetitive transcranial magnetic stimulation:1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex , each consisting of 4 days of rTMS treatment.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train.
Study NCT02617953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS(B)
Description: repetitive transcranial magnetic stimulation:1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex , each consisting of 4 days of rTMS treatment.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train.
Study NCT02617953 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham condition(C)
Description: The sham stimulation looks and sounds like the active coil, but diverts the magnetic field away from the patient.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train.
Study NCT03240822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Penile Transplant
Description: Penile Allotransplantation
Study NCT03240822 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monoclonal Antibody (Humanized Anti-CD52)
Study NCT03240822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study NCT00297947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: Participant will receive 1200 mg/day of quetiapine in twice daily dosing for 8 weeks.
Study NCT00297947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: Participant will receive 600 mg/day of quetiapine for 8 weeks.
Study NCT03909490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preference elicitation tool
Description: Ranking tool to assess patient preferences for trigger finger treatment
Study NCT03909490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: handout
Description: handout with information about trigger fingers
Study NCT01052610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sublingual house dust mites allergen extract
Description: Staloral 300 IR, Stallergenes, France
Study NCT01052610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo in sublingual applicator
Description: placebo for Staloral 300 IR, Stallergenes, France